Israeli Biotech Partners with Norwegian Firm on New Brain Cancer Drug

Jerusalem, 29 September, 2025 (TPS-IL) — BioLineRx Ltd., an Israeli biopharmaceutical company, has partnered with Oslo-based Hemispherian AS to develop GLIX1, a new oral drug for glioblastoma and other cancers. GLIX1 targets cancer cells’ DNA repair, causing tumor-specific cell death while leaving healthy cells intact. The FDA has cleared an Investigational New Drug application, with a Phase 1/2a trial expected to start in early 2026.

BioLineRx will manage and fund the project, initially holding a 40% stake, while Hemispherian owns 60%.